Table 1.
Clinical characteristics of 782 temporal lobes.
| Characteristics | All | Primary Cohort | Validation Cohort | P |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | ||
| Total | 782 | 388 | 394 | |
| Sex | 0.071 | |||
| Male | 545(69.7%) | 282(72.7%) | 263(66.8%) | |
| Female | 237(30.3%) | 106(27.3%) | 131(33.2%) | |
| Age(years) | 0.005 | |||
| ≤60 | 688(88.0%) | 354(91.2%) | 334(84.8%) | |
| >60 | 94(12.0%) | 34(8.8%) | 60(15.2%) | |
| T stage (AJCC8th) | 0.247 | |||
| T1 | 36(4.6%) | 18(4.6%) | 18(4.65) | |
| T2 | 286(36.6%) | 149(38.4%) | 137(34.8%) | |
| T3 | 216(27.6%) | 113(29.1%) | 103(26.1%) | |
| T4 | 244(31.2%) | 108(27.8%) | 136(34.5%) | |
| N stage (AJCC8th) | 0 | |||
| N0 | 36(4.6%) | 28(7.2%) | 8(2%) | |
| N1 | 120(15.3%) | 70(18%) | 50(12.7%) | |
| N2 | 521(66.6%) | 252(64.9%) | 269(68.3%) | |
| N3 | 105(13.4%) | 38(9.8%) | 67(17%) | |
| Hypertension | 0.256 | |||
| Yes | 48(6.1%) | 20(5.2%) | 28(7.1%) | |
| No | 734(93.9%) | 368(94.8%) | 366(92.9%) | |
| Diabetes | 0.742 | |||
| Yes | 31(4.0%) | 15(3.8%) | 16(4.1%) | |
| No | 751(96.0%) | 373(96.2%) | 378(95.9%) | |
| Smoking | 0.905 | |||
| Yes | 308(39.4%) | 152(39.2%) | 156(39.6%) | |
| No | 474(60.6%) | 236(60.8%) | 238(60.4%) | |
| Alcoholism | 0.007 | |||
| Yes | 216(27.6%) | 124(32.0%) | 92(23.4%) | |
| No | 566(72.4%) | 264(68.0%) | 302(76.6%) | |
| Cholesterol | 0.206 | |||
| ≤5.2 mmol/L | 576(73.7%) | 278(71.6%) | 298(75.6%) | |
| >5.2 mmol/L | 206(26.3%) | 110(28.4%) | 96(24.4%) | |
| Triglycerides | 0.544 | |||
| ≤1.7 mmol/L | 532(68.0%) | 260(67.0%) | 272(69.0%) | |
| >1.7 mmol/L | 250(32.0%) | 128(33.0%) | 122(31.0%) | |
| NLR | 0 | |||
| ≤2.82 | 456(58.3%) | 202(52.1%) | 254(64.5%) | |
| >2.82 | 326(41.7%) | 186(47.9%) | 140(35.5%) | |
| PLR | 0.027 | |||
| ≤117.53 | 422(54.0%) | 194(50%) | 228(57.9%) | |
| >117.53 | 360(46%) | 194(50%) | 166(42.1%) | |
| Target therapy | 0.774 | |||
| Yes | 134(17.1%) | 68(17.5%) | 66(16.8%) | |
| No | 648(82.9%) | 320(82.5%) | 328(83.2%) | |
| ART | 0.465 | |||
| Yes | 284(36.3%) | 136(35.1%) | 148(37.6%) | |
| No | 498(63.7%) | 252(64.9%) | 246(62.4%) | |
| TLI | 0.164 | |||
| Yes | 117(15%) | 65(16.8%) | 52(13.2%) | |
| No | 665(85%) | 323(83.2%) | 342(86.8%) |
NLR, neutrophil-to-lymphocyte ratios; PLR, platelets-to-lymphocyte ratios; ART, adaptive radiation therapy; TLI, temporal lobe injury.